For Alkermes' Vivitrol, FDA Not Viewing Trial Results From Russia With Love
This article was originally published in The Pink Sheet Daily
Executive Summary
Underreporting of adverse events may be a Russian "cultural norm," the agency says in a briefing document released in advance of an advisory panel review of Alkermes' Vivitrol (naltrexone) for opioid dependence.